戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ith the triphosphate forms of sofosbuvir and aciclovir.
2 d for no medication (28.7) and standard-dose aciclovir (10.0; p=0.001).
3 ger for no medication than for standard-dose aciclovir (13 h vs 7 h; p=0.01) and for standard-dose va
4  standard-dose valaciclovir versus high-dose aciclovir (2.7 vs 2.8; p=0.66).
5 rd-dose valaciclovir (22.6) versus high-dose aciclovir (20.2; p=0.54), and standard-dose valaciclovir
6 her for no medication than for standard dose aciclovir (3.3 vs 2.9; p=0.02), and for standard-dose va
7 signed by block randomisation to twice daily aciclovir 400 mg (n=1637) or matching placebo (n=1640) f
8  numbers in blocks of four to receive either aciclovir 400 mg orally twice daily or placebo; particip
9 ss-over studies comparing no medication with aciclovir 400 mg twice daily (standard-dose aciclovir),
10 een standard-dose valaciclovir and high-dose aciclovir (8 h vs 8 h; p=0.23).
11 0 mg daily (standard-dose valaciclovir) with aciclovir 800 mg three times daily (high-dose aciclovir)
12 tiretrovirals, such as the anti-herpes drugs Aciclovir and Ganciclovir and the anti-cancer drug Clofa
13 ciclovir 800 mg three times daily (high-dose aciclovir), and standard-dose valaciclovir with valacicl
14 se with CD4 counts >or=350 cells per microL, aciclovir delayed risk of CD4 cell counts falling to <35
15 4, 18.1% of swabs) than in the standard-dose aciclovir group (25, 1.2%; incidence rate ratio [IRR] 0.
16 of HIV-1 was 3.9 per 100 person-years in the aciclovir group (75 events in 1935 person-years of follo
17 cebo group, and 85% of expected doses in the aciclovir group and 86% in the placebo group.
18 rence to dispensed study drug was 94% in the aciclovir group and 94% in the placebo group, and 85% of
19 at 18 months in both groups (1028 of 1212 in aciclovir group, 1030 of 1208 in placebo group).
20 ere included in the primary dataset (1581 in aciclovir group, 1591 in control group).
21 ital ulcers by 63% (0.37 [0.31-0.45]) in the aciclovir group.
22 t suppressive therapy with standard doses of aciclovir is not effective in reduction of HIV-1 acquisi
23                                  Suppressive aciclovir might be warranted for individuals dually infe
24 investigated the effect of daily suppressive aciclovir on HIV-1 disease progression in Rakai, Uganda.
25 onsisted of cotrimoxazole, itraconazole, and aciclovir (or valganciclovir for asymptomatic cytomegalo
26                                              Aciclovir reduces the rate of disease progression, with
27                  No safety issues related to aciclovir treatment were identified.
28  aciclovir 400 mg twice daily (standard-dose aciclovir), valaciclovir 500 mg daily (standard-dose val
29                                    High-dose aciclovir was associated with less shedding than standar
30  investigated whether HSV-2 suppression with aciclovir would reduce the risk of HIV-1 acquisition.